Esmo 2024 Programme Meaning. Cullinan therapeutics presents positive updated data from module c of zipalertinib pivotal phase 2b study at esmo 2024. At the esmo congress 2024, the programme delivers the latest scientific advancements and also addresses the broader aspects of oncology.
Once the platform is closed, from 20 september 2024, webcasts will be available on oncologypro for all registered delegates and esmo members. Group b response and control rates based on n=17.
